<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076890</url>
  </required_header>
  <id_info>
    <org_study_id>Gaia-19002</org_study_id>
    <nct_id>NCT05076890</nct_id>
  </id_info>
  <brief_title>Hemp 15 mg &amp; 50 mg Capsule Absorption</brief_title>
  <official_title>Hemp 15 mg &amp; 50 mg Capsule Absorption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gaia Herbs Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Appalachian College of Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gaia Herbs Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to investigate the absorption of cannabidiol (CBD) and cannabidiol&#xD;
      acid (CBD-A) in plasma from an oral delivery of a single dose of full spectrum hemp extract&#xD;
      at two concentrations over a 4-hour timeline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to determine the time to maximum plasma concentration of CBD and CBD-A&#xD;
      after an oral dose of standardized full spectrum hemp extract over a 4-hour timeline. This&#xD;
      study is designed to include two arms. Each arm will be delivered a different concentration&#xD;
      of standardized full spectrum hemp extract, either 15 mg or 50 mg. Throughout the course of&#xD;
      the study all participants will be asked to provide four (4) plasma samples, 10 randomly&#xD;
      selected participants will be asked to provide five (5) plasma samples. Samples will then be&#xD;
      evaluated using a validated LC-MS/MS method to develop a blood concentration time curve in&#xD;
      order to determine time to reach maximum blood concentration. This trial is double-blinded&#xD;
      with two arms enrolling only healthy individuals. The participants randomized for a fifth&#xD;
      blood draw will be randomly selected from these two arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to maximum plasma concentration</measure>
    <time_frame>Over 4 hours</time_frame>
    <description>To determine the time to maximum plasma concentration of cannabidiol (CBD) and cannabidiol acid (CBD-A) from an oral delivery of a single dose of standardized 15 mg or 50 mg full spectrum hemp extract</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detectable THC</measure>
    <time_frame>Over 4 hours</time_frame>
    <description>To determine if the oral delivery of a full spectrum hemp extract standardized to less than 0.3% ∆^9- tetrahydrocannabinol (THC) results in detectable amounts of THC in plasma.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Present in measurable amount over time</measure>
    <time_frame>7 - 10 days</time_frame>
    <description>To determine if CBD, CBD-A, or THC are present 7 to 10 days after a single oral dose of 15 mg or 50 mg standardized full spectrum hemp extract.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Absorption; Chemicals</condition>
  <arm_group>
    <arm_group_label>15 mg/g Full Spectrum Hemp Extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single capsule of 15 mg/g Full Spectrum Hemp Extract will be delivered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg/g Full Spectrum Hemp Extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single capsule of 50 mg/g Full Spectrum Hemp Extract will be delivered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>15 mg/g Full Spectrum Hemp Extract</intervention_name>
    <description>HPMC capsules containing full spectrum standardized hemp extract in liquid form.</description>
    <arm_group_label>15 mg/g Full Spectrum Hemp Extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>50 mg/g Full Spectrum Hemp Extract</intervention_name>
    <description>HPMC capsules containing full spectrum standardized hemp extract in liquid form.</description>
    <arm_group_label>50 mg/g Full Spectrum Hemp Extract</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form.&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study.&#xD;
&#xD;
          3. Ages 18 - 65.&#xD;
&#xD;
          4. In good general health as evidenced by medical history as indicated by oral&#xD;
             confirmation of study participant.&#xD;
&#xD;
          5. Ability and willingness to suspend the use of any other herbal dietary supplements for&#xD;
             48 hours prior the first clinical visit associated with this study.&#xD;
&#xD;
          6. Ability and willingness to abstain from alcohol use for 12 hours prior to the first&#xD;
             clinical visit.&#xD;
&#xD;
          7. Cannabis and CBD naïve for 60 days or more prior to enrolling in the study.&#xD;
&#xD;
          8. Ability and willingness to abstain from food for 6 hours prior to the first clinical&#xD;
             visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current use of regular medication for a chronic condition.&#xD;
&#xD;
          2. Current pregnancy or lactation.&#xD;
&#xD;
          3. Plans to become pregnant during the intended duration of the study.&#xD;
&#xD;
          4. Known allergic reactions to hemp flower.&#xD;
&#xD;
          5. Known severe food allergies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Faisal Hossain, PhD</last_name>
    <phone>276-498-5240</phone>
    <email>mhossain@acp.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brent Gravelle, PhD, MD</last_name>
    <phone>276-639-8250</phone>
    <email>bgravelle@acp.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Appalachian College of Pharmacy</name>
      <address>
        <city>Oakwood</city>
        <state>Virginia</state>
        <zip>24631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faisal Hossain, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Brent Gravelle, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

